Rigel Pharmaceuticals Financials - Benzinga

Rigel Pharmaceuticals Inc

RIGLNASDAQ

Trade with Public

Trade with Public

$46.48

-0.38-0.81%

At close: Aug 27, 5:00 PM EST

$46.48

-0.38-0.81%

Pre-Market: 3:00 AM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Rigel Pharmaceuticals Financials

Rigel Pharmaceuticals (RIGL) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Rigel Pharmaceuticals Raises FY2026 Sales Guidance from $275.000M-$290.000M to $285.000M-$295.000M vs $308.461M Est

Rigel Pharmaceuticals (NASDAQ:RIGL) raises FY2026 sales outlook from $275.000 million-$290.000 million to $285.000 million-$295.000 million vs $308.461 million estimate.

Benzinga Newsdesk

PRO
Rigel Pharmaceuticals Q2 EPS $0.88 Beats $0.62 Estimate, Sales $78.700M Beat $69.463M Estimate

Rigel Pharmaceuticals (NASDAQ:RIGL) reported quarterly earnings of $0.88 per share which beat the analyst consensus estimate of $0.62 by 41.94 percent. This is a 73.17 percent decrease over earnings of $3.28 per share

Benzinga Newsdesk

These Analysts Increase Their Forecasts On Arvinas After Q1 Results

Arvinas Inc (NASDAQ:ARVN) reported Q1 losses of 90 cents/share, missed analyst estimates. Rigel Pharmaceuticals (NASDAQ:RIGL) announced global licensing agreement with Arvinas and Pfizer (NYSE:PFE) for oral PROTAC drug VEPPANU. Arvinas shares rose 1.7% on Wednesday and analysts have raised price targets.

Avi Kapoor

PRO
Rigel Pharmaceuticals Affirms FY2026 Sales Guidance of $275.000M-$290.000M vs $284.068M Est

Rigel Pharmaceuticals (NASDAQ:RIGL) affirms FY2026 sales outlook from $275.000 million-$290.000 million to $275.000 million-$290.000 million vs $284.068 million estimate.

Benzinga Newsdesk

PRO
Rigel Pharmaceuticals Q1 EPS $0.44 Misses $0.76 Estimate, Sales $58.800M Miss $62.392M Estimate

Rigel Pharmaceuticals (NASDAQ:RIGL) reported quarterly earnings of $0.44 per share which missed the analyst consensus estimate of $0.76 by 42.11 percent. This is a 30.16 percent decrease over earnings of $0.63 per share

Benzinga Newsdesk

Earnings Scheduled For May 5, 2026

Benzinga Insights